1. Home
  2. MRLN vs DSGN Comparison

MRLN vs DSGN Comparison

Compare MRLN & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MRLN

Merlin Inc. Common Stock

N/A

Current Price

$8.09

Market Cap

915.1M

Sector

Technology

ML Signal

N/A

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

HOLD

Current Price

$10.47

Market Cap

819.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MRLN
DSGN
Founded
2018
2017
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
915.1M
819.6M
IPO Year
2024
2021

Fundamental Metrics

Financial Performance
Metric
MRLN
DSGN
Price
$8.09
$10.47
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$25.00
$15.25
AVG Volume (30 Days)
1.5M
1.1M
Earning Date
10-28-2021
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.78
$3.33
52 Week High
$17.00
$17.25

Technical Indicators

Market Signals
Indicator
MRLN
DSGN
Relative Strength Index (RSI) 47.80 37.06
Support Level $6.07 $9.36
Resistance Level $17.00 $10.59
Average True Range (ATR) 0.85 1.29
MACD 0.19 -0.38
Stochastic Oscillator 76.66 6.83

Price Performance

Historical Comparison
MRLN
DSGN

About MRLN Merlin Inc. Common Stock

Merlin Inc is focused on developing autonomous flight software for legacy and next-generation airborne systems. Its aircraft-agnostic, AI-based software supports takeoff-to-landing autonomous operations for military and civil aviation programs. The company aims to build an AI-based operating software platform intended to support autonomous flight operations across a range of aircraft types.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

Share on Social Networks: